Bio
Janet M. Sasso earned her B.S. in Biology from The Ohio State University (OSU). She also holds her Master of Public Health from OSU where she focused her research on public health equity and education. She joined CAS in 2006 as an Information Scientist in the life sciences department curating pharmacology, pharmaceutical, environmental science, and toxicological research information. She is passionate about scientific communication to accelerate scientific analysis and inspire advancement worldwide.
Emerging Science
Latest developments in the global mpox outbreak
With recent headlines on monkeypox, learn more about the research landscape, scientific profiles, and currently available therapies. A deeper understanding of the published science enables clarity and insight on this emerging news story.
Materials
Webinar: Emerging areas in biomaterials - Reshaping medicine and human health
Biomaterials are making an impact on health and medicine. Experts from CAS, Ortholevo, and Westlake University discuss the full landscape.
Drug Discovery
Rare diseases and orphan diseases: Can combination therapy treat them?
How combination therapies including drug repurposing, cell therapy, and genetic therapy are leading to improved treatment of rare diseases.
Emerging Science
Decoding neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's
Uncover the latest advancements in understanding and treating neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s.
Emerging Science
Webinar: Scientific breakthroughs and emerging trends to watch in 2024
Experts from Lawrence Livermore National Lab, Oak Ridge National Lab, The Ohio State University, and CAS discuss major research trends in 2024.
Biotechnology
How biomarkers unlock faster cancer detection, improving outcomes
As cancer is projected to increase, finding stronger therapeutics is more urgent. Biomarkers offer a potential solution for better diagnosis and treatment.
Emerging Science
Biomarkers: The key to earlier cancer detection and patient outcomes
CAS and Excelra delved into data surrounding biomarkers and their relationship to cancer to identify key targets for future study.
Drug Discovery
Unveiling the potential of the antibody drug conjugate
Since 2018, research interest in antibody-drug conjugates has increased exponentially, due to their potential in the fight against cancer.
Emerging Science
Webinar on gut microbiome-brain alliance: The connection to health and disorders
CAS, Bayer, and Caltech explore how the gut-brain axis influences health from IBS to autism.
Biotechnology
Webinar on nature’s lipid nanoparticles: Exosomes
Exosomes have enormous potential in drug delivery, diagnostics, and more. Mayo Clinic, Direct Biologics, and Aruna Bio discuss the full landscape.
Drug Discovery
Exosome research: from platelet dust to pioneering therapeutics
Landscape view of emerging contributors, companies, and researchers in the emerging field of exosome research. This article overviews key players in diagnostics and therapeutic fields of exosome research with a deeper look into the current clinical pipeline.
Drug Discovery
ACS webinar on molecular glues and targeted protein degradation
Expert panelists include Dr. Benjamin Ebert, the chair of Medical Oncology at the Dana-Farber Institute, Dr. Phil Chamberlain, the co-founder, President, and CEO of Neomorph, and Janet Sasso, an information scientist specializing in Life Sciences at CAS.
Digital R&D
The rise of AI drug development technology
Drug development is rapidly changing, which requires pharma companies to pivot. This is where AI drug development comes in, applying new technology to tackle an old problem.
Drug Discovery
Why the omicron BA.5 variant evades vaccines
As COVID-19 cases rise again worldwide, the Omicron subvariant BA.5 is currently the dominant strain. This blog explores some key mutations that increase transmission, evade protective antibodies, and increase the rate of (re)infection.
Biotechnology
Molecular glues and induced proximity: solving the undruggable
Molecular glues have been used to uncover new therapeutic agents. Because of their targeted protein degradation that holds them together, these glues have exciting potential in uncovering new drugs to fight cancer, immune diseases, and more.
Biotechnology
A therapeutic revolution: RNA in COVID-19 and beyond
We are in the midst of a therapeutic revolution, according to the authors of a recent review article in Frontiers in Bioengineering and Biotechnology.
Biotechnology
COVID-19 vaccine boosters: what does the research show?
With recent mRNA booster recommendations, many ask if they should get a COVID-19 booster and what the science shows? This blog explains the science of boosters, reviews current recommendations, and examines recent research.